Decode the Impact of SARS-CoV-2 on Human Pancreas
Decode the Impact of SARS-CoV-2 on Human Pancreas
批准号:
10646228
负责人:
Shuibing Chen
金额:
$42.26万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-07-05 至 2024-06-30
关键词:
2019-nCoVACE2Acinar CellAlpha CellAutopsyBeta CellCOVID-19COVID-19 detectionCOVID-19 impactCOVID-19 mortalityCOVID-19 pandemicCOVID-19 patientCOVID-19 susceptibilityCell physiologyCellsCellular StressCessation of lifeClinicalClinical DataClinical ResearchCompensationCytokine SignalingCytometryDataDefectDevelopmentDiabetes MellitusDiseaseDuctal Epithelial CellEndocrineEndothelial CellsEukaryotic Initiation Factor-2EventFunctional disorderGlucagonHumanImageImpairmentIndividualInfectionInflammationInsulinInsulin ResistanceInsulin-Dependent Diabetes MellitusIslet CellIslets of LangerhansLaboratoriesMacrophageMetabolicModelingMorbid ObesityNRP1 geneNon-Insulin-Dependent Diabetes MellitusOrganoidsOutcomePancreasPancreatic ductParacrine CommunicationPathogenesisPathologicPathologyPathway interactionsPatientsPhenotypePlayPublishingResearch PersonnelRisk FactorsRoleSARS-CoV-2 infectionSamplingSignal TransductionSpecimenStructure of beta Cell of isletTechnologyTestingTherapeuticTissuesTrypsinVascularizationVirusautoimmune pathogenesischemokinehigh riskimaging systemimmune cell infiltrateisletmultidisciplinarynovel therapeuticspandemic diseaseparacrinephysiologic modelsevere COVID-19single-cell RNA sequencingstem cellstransdifferentiation
中文摘要
抽象的。
最近的临床数据表明,冠状病毒疾病19(COVID-19)和
糖尿病
患有糖尿病和严重肥胖的人更有可能
并发症,并有较高的COVID-19
死亡率
症状性
.相反,新发糖尿病和严重
的风险更高,
已在COVID-19患者中观察到既存糖尿病的代谢并发症。因此,有一个
强烈需要了解COVID-19患者胰腺功能障碍的病理和机制。在这里,
我们证明了在COVID-19尸检样本的胰腺内分泌细胞中检测到SARS-CoV-2
患者单细胞RNA-seq和免疫染色证实,多种类型的胰岛细胞是
对SARS-CoV-2易感,引发细胞应激反应和诱导趋化因子。在SARS期间-
CoV-2感染后,β细胞显示胰岛素表达减少,α和β细胞表达增加。
腺泡细胞标志物,分别包括胰高血糖素和PRSS 1/胰蛋白酶1,提示细胞
转分化
尸检标本致病性检验的自动化技术
COVID-19患者。此外,我们将使用人类胰岛和血管化的人类胰腺类器官
系统评价直接感染和旁分泌炎症信号在人类
内分泌细胞的细胞特性、功能和存活。
在提案中,我们将采用最先进的
通过这项研究,我们希望提供一个
系统概述了COVID-19患者胰腺的病理变化,并详细介绍了
了解内分泌细胞功能障碍的机制,这将为开发新的
保护COVID-19患者内分泌细胞功能的治疗。
英文摘要
Abstract.
Recent clinical data has suggested a bidirectional interaction between Coronavirus disease 19 (COVID-19) and
diabetes.
Individuals with diabetes and severe obesity are more likely to be
complications, and have a higher COVID-19
mortality rate
symptomatic
. Conversely, new-onset diabetes and severe
, are at a higher risk for
metabolic complications of pre-existing diabetes have been observed in COVID-19 patients. Thus, there is a
strong need to understand the pathology and mechanism of pancreatic dysfunction in COVID-19 patients. Here,
we demonstrate the detection of SARS-CoV-2 in pancreatic endocrine cells in autopsy samples from COVID-19
patients. Single cell RNA-seq and immunostaining confirmed that multiple types of pancreatic islet cells are
susceptible to SARS-CoV-2, eliciting a cellular stress response and the induction of chemokines. Upon SARS-
CoV-2 infection, beta cells show a decreased expression of insulin and the increased expression of alpha and
acinar cell markers, including glucagon and PRSS1/trypsin1, respectively, suggesting cellular
transdifferentiation.
Hyperion technology to examine the pathogenesis of autopsy samples
of COVID-19 patients. In addition, we will use human islets and a vascularized human pancreatic organoid
models to systematically evaluate the role of direct infection and paracrine inflammation signal on human
endocrine cells cellular identities, function and survival.
In the proposal, we will apply state-of-art
Through this study, we would expect to provide a
systematic overview of the pathological changes in the pancreas of COVID-19 patients, as well as a detailed
mechanism to understand endocrine cell dysfunction, which will pave the road to the development of novel
therapy to protect endocrine cell function in COVID-19 patients.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.stem.2022.09.008
发表时间:
2022-10-06
期刊:
CELL STEM CELL
影响因子:
23.9
作者:
[Han, Yuling, Tan, Lei, Zhou, Ting, Yang, Liuliu, Carrau, Lucia, Lacko, Lauretta A., Saeed, Mohsan, Zhu, Jiajun, Zhao, Zeping, Nilsson-Payant, Benjamin E., Neto, Filipe Tenorio Lira, Cahir, Clare, Giani, Alice Maria, Chai, Jin Chou, Li, Yang, Dong, Xue, Moroziewicz, Dorota, Paull, Daniel, Zhang, Tuo, Koo, Soyeon, Tan, Christina, Danziger, Ron, Ba, Qian, Feng, Lingling, Chen, Zhengming, Zhong, Aaron, Wise, Gilbert J., Xiang, Jenny Z., Wang, Hui, Schwartz, Robert E., tenOever, Benjamin R., Noggle, Scott A., Rice, Charles M., Qi, Qibin, Evans, Todd, Chen, Shuibing]
通讯作者:
Chen, Shuibing
DOI:
10.1016/j.stem.2023.04.011
发表时间:
2023-05-04
期刊:
CELL STEM CELL
影响因子:
23.9
作者:
[Vandana, J. Jeya, Manrique, Cassandra, Lacko, Lauretta A., Chen, Shuibing]
通讯作者:
Chen, Shuibing
Abnormal Extracellular Vesicles and Particles from Human Islets Impact T1D progression
-
批准号:10754074
-
项目类别:
-
资助金额:$72.91万
-
财政年份:2023
-
负责人:Shuibing Chen
-
依托单位:
Decode the Impact of SARS-CoV-2 on Human Pancreas
-
批准号:10319780
-
项目类别:
-
资助金额:$44.01万
-
财政年份:2021
-
负责人:Shuibing Chen
-
依托单位:
Decode the Impact of SARS-CoV-2 on Human Pancreas
-
批准号:10443871
-
项目类别:
-
资助金额:$42.26万
-
财政年份:2021
-
负责人:Shuibing Chen
-
依托单位:
A High Content Chemical Screen to Identify the Drug Candidates Promoting Human Beta Cell Proliferation
-
批准号:10343755
-
项目类别:
-
资助金额:$42.38万
-
财政年份:2020
-
负责人:Shuibing Chen
-
依托单位:
A High Content Chemical Screen to Identify the Drug Candidates Promoting Human Beta Cell Proliferation
-
批准号:10571823
-
项目类别:
-
资助金额:$42.38万
-
财政年份:2020
-
负责人:Shuibing Chen
-
依托单位:
A High Content Chemical Screen to Identify the Drug Candidates Promoting Human Beta Cell Proliferation
-
批准号:10117247
-
项目类别:
-
资助金额:$42.38万
-
财政年份:2020
-
负责人:Shuibing Chen
-
依托单位:
Determining the Intrinsic and Environmental Signal Contributing to Early T1D Progression
-
批准号:10262967
-
项目类别:
-
资助金额:$76.26万
-
财政年份:2020
-
负责人:Shuibing Chen
-
依托单位:
Determining the Intrinsic and Environmental Signal Contributing to Early T1D Progression
-
批准号:10440517
-
项目类别:
-
资助金额:$75.32万
-
财政年份:2020
-
负责人:Shuibing Chen
-
依托单位:
Determining the Intrinsic and Environmental Signal Contributing to Early T1D Progression
-
批准号:10157473
-
项目类别:
-
资助金额:$78.78万
-
财政年份:2020
-
负责人:Shuibing Chen
-
依托单位:
Determining the Intrinsic and Environmental Signal Contributing to Early T1D Progression
-
批准号:10653103
-
项目类别:
-
资助金额:$74.49万
-
财政年份:2020
-
负责人:Shuibing Chen
-
依托单位:
Metallothionein 1E as a Central Regulator of Human Pancreatic Beta Cell Function and Survival
-
批准号:10220173
-
项目类别:
-
资助金额:$39.77万
-
财政年份:2019
-
负责人:Shuibing Chen
-
依托单位:
Metallothionein 1E as a Central Regulator of Human Pancreatic Beta Cell Function and Survival
-
批准号:10190924
-
项目类别:
-
资助金额:$80.99万
-
财政年份:2019
-
负责人:Shuibing Chen
-
依托单位:
Metallothionein 1E as a Central Regulator of Human Pancreatic Beta Cell Function and Survival
-
批准号:10409781
-
项目类别:
-
资助金额:$43.22万
-
财政年份:2019
-
负责人:Shuibing Chen
-
依托单位:
A High Throughput Screening to Identify Compounds Rescuing Human Pancreatic Beta Cell Function in Diabetic Conditions
-
批准号:9905514
-
项目类别:
-
资助金额:$42.38万
-
财政年份:2018
-
负责人:Shuibing Chen
-
依托单位:
Studying Progression and Regression of Beta Cell Dysfunction in Type 2 Diabetes
-
批准号:9085758
-
项目类别:
-
资助金额:$6.69万
-
财政年份:2012
-
负责人:Shuibing Chen
-
依托单位:
Studying the Progression and Regression of Beta Cell Dysfunction in Type 2 Diabet
-
批准号:8358417
-
项目类别:
-
资助金额:$245.96万
-
财政年份:2012
-
负责人:Shuibing Chen
-
依托单位:
国内基金
海外基金
登录
查看更多内容
ACE2/AGXT2信号轴在甲基异柳磷诱导斑马鱼神经发育异常过程中的作用机制研究
-
批准号:JCZRLH202600625
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
ACE2 Ser623磷酸化调控MED1促VSMCs功能损伤在移植血管重构中的作用及机制研究
-
批准号:2026JJ50619
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:翁春艳
-
依托单位:
AURKA介导ACE2磷酸化修饰调控内皮细胞衰老在低氧性肺动脉高压中的作用及机制研究
-
批准号:82570085
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2025
-
负责人:沈慧
-
依托单位:
牛蒡叶倍半萜成分群激活ACE2/Ang1-7/MasR轴调控血管内皮—周细胞互作促缺血性脑卒中血管正常化机制研究
-
批准号:82404910
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2024
-
负责人:郝单丽
-
依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
ACE2通过AMPK/SIRT3调控线粒体代谢改善盐敏感性高血压肾脏纤维化的机制
-
批准号:82460087
-
项目类别:地区科学基金项目
-
资助金额:33.00万元
-
批准年份:2024
-
负责人:赵宇
-
依托单位:
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介
导“肠-胰岛 ”轴血糖调控功能的降糖机制研
究
-
批准号:Y24H280055
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:颜美秋
-
依托单位:
人类ACE2变构抑制剂的成药性及其抗广谱冠状病毒感染的机制研究
-
批准号:82330111
-
项目类别:重点项目
-
资助金额:220万元
-
批准年份:2023
-
负责人:刘刚
-
依托单位:
CAFs来源的外泌体负性调控ACE2促进肾透明细胞癌癌栓新辅助靶向耐药的机制研究
-
批准号:82373169
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:顾良友
-
依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2受体识别及细胞入侵机制研究
-
批准号:32300137
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:陈静
-
依托单位: